The global Radiation Proctitis market gathered revenue around USD 372 Million in 2020 and market is set to grow USD 750.2 Million by the end of 2030. The global Radiation Proctitis market is estimated to expand at a modest CAGR of 7.7% during the prediction period 2021 to 2030. Radiation proctitis is a condition, in which the lining tissue of the inner rectum becomes inflamed. The rectum is a muscular tube that is connected to the end of colon through which stool is passed out of the body. This occurs as a result of damage to the rectum sustained from pelvic radiation given to treat a cancer such as prostate or cervical. Increase in incidence of urinary diseases, surge in the global geriatric population, and rise in prevalence of chronic radiation proctitis are major factors anticipated to drive the global radiation proctitis market during the forecast period.
North America held a major share of the global radiation proctitis market in 2020, due to large population undergoing radiation therapy for the treatment of prostate cancer, bladder cancer, gynecologic cancer, rectal cancer, and lymphoma.
Radiation proctitis is inflammation of the rectum due to exposure of X rays or other ionizing radiation. The management of radiation proctitis is divided into invasive and non-invasive treatment. Non-invasive treatment includes anti-inflammatory agents, sucralfate, short-chain fatty acids, hyperbaric, and antioxidants.
This research report purposes at stressing the most lucrative growth prospects.The aim of the research report is to provide an inclusive valuation of the Radiation Proctitis market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Radiation Proctitis market reportaids in comprehendingmarket structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
COVID-19 Impact Assessment on Market Landscape
Healthcare facilities such as the Hyperbaric Medical Solutions is taking extra preventive steps to mitigate the risks of the coronavirus pandemic to ensure all patients are offered clean and safe environments. Stakeholders in the radiation proctitis market are increasing efforts to boost the availability for hyperbaric oxygen therapy (HBOT), which is being associated with enhancing the immune system in the wake of the COVID-19 outbreak.
The report comprises the scrutiny of COVID-19 lock-downimpact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilaracross various industry verticals. The research reportofferspresent short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lastingtactics for recovery and by region.
Radiation Proctitis market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplish sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share.Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Significant Market Participants Operational in the Radiation Proctitis Market are:
The global radiation proctitis market are Allergan plc, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Pfizer, Inc., Mylan, Inc., (Viatris), Sanofi, Johnson & Johnson (Johnson & Johnson Consumer, Inc.), Sun Pharmaceutical Industries Ltd., Environmental Tectonics Corporation, and Sechrist Industries, Inc. In December 2016, Sun Pharmaceutical Industries Ltd.
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects includingproduct type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2030 and covers subsequent region in its scope:
Global Radiation Proctitis Market: Segmentation
- Radiation Proctitis Market, by Indication
- Acute Radiation Proctitis
- Chronic Radiation Proctitis
- Radiation Proctitis Market, by Therapy
- Oral Therapy
- Antidiarrheals
- Anti-inflammatory Agents
- Others
- Ablative Procedures
- Hyperbaric Oxygen Therapy
- Formalin
- Surgery
By Regional Outlook
North America
Europe
- Germany
- United Kingdom
- Italy
- France
- Rest of EU
Asia Pacific
- China
- India
- Japan
- Southeast Asia
- Rest of APAC
Central & South America
- Brazil
- Argentina
- Rest of Central & South America
Middle East and Africa
- GCC
- North Africa
- South Africa
Request Customization
Get a Sample
Get a Sample
Request Customization